EVE Health Group’s subsidiary Nextract has inked a pivotal two-year agreement with TeleDocs Clinic, enabling nationwide online prescribing of its upcoming erectile dysfunction and dysmenorrhea products ahead of regulatory approval.
- Two-year national prescribing and marketing agreement signed with TeleDocs Clinic
- TeleDocs becomes first online clinic authorised to prescribe EVE’s Libbo+ and Dyspro
- Products target erectile dysfunction (oral soluble film) and dysmenorrhea (gummy)
- TeleDocs to support practitioner education and digital integration across 3,500+ pharmacies
- Regulatory submissions and manufacturing planned for Q3/Q4 2025
Strategic Partnership to Expand Patient Access
EVE Health Group (ASX – EVE) has taken a significant step towards commercialising its novel pharmaceutical products with a new national prescribing agreement. Its wholly owned subsidiary, Nextract Pty Ltd, has partnered with TeleDocs Clinic & Consulting Pty Ltd to enable online prescribing of Libbo+, an oral soluble film for erectile dysfunction, and Dyspro, a gummy formulation aimed at managing dysmenorrhea.
This two-year agreement positions TeleDocs as the first telehealth provider authorised to prescribe both products across Australia. With a network spanning over 3,500 pharmacies nationwide, TeleDocs will play a crucial role in facilitating patient access and supporting EVE’s product launch strategy.
Enhancing Practitioner Support and Digital Integration
Beyond prescribing, TeleDocs will provide extensive clinical training and digital education to healthcare practitioners. The partnership includes developing decision support tools, integrating the products into major prescribing software platforms, and promoting awareness through newsletters and professional education databases.
These initiatives aim to ensure that practitioners and pharmacies are well-equipped to recommend and dispense the new treatments safely and effectively, enhancing the overall patient experience.
Products Nearing Market Readiness
Libbo+ and Dyspro are currently in the final stages of formulation and stability testing. EVE anticipates submitting regulatory applications and commencing manufacturing in the third and fourth quarters of 2025. The collaboration with TeleDocs is designed to streamline market entry once approvals are secured.
Executive Director Stuart Gunzburg highlighted the importance of TeleDocs’ digital health expertise and national reach, describing the partnership as vital for launching treatments that address unmet clinical needs at scale.
Looking Ahead
While pricing terms remain to be finalised, the agreement includes quarterly reporting on prescribing activity and compliance, ensuring transparency and alignment between the parties. The collaboration also commits both companies to maintaining branding integrity and regulatory compliance throughout the product rollout.
As EVE prepares for regulatory milestones later this year, this partnership sets the stage for a potentially transformative entry into the Australian pharmaceutical market, leveraging telehealth and pharmacy networks to broaden patient access.
Bottom Line?
EVE’s alliance with TeleDocs could redefine access to sexual and women’s health treatments, but regulatory and pricing hurdles remain key watchpoints.
Questions in the middle?
- When exactly will regulatory approvals for Libbo+ and Dyspro be granted?
- What pricing strategy will EVE and TeleDocs agree upon prior to launch?
- How quickly will TeleDocs’ network translate into meaningful prescribing volumes?